About Addex Therapeutics
Addex Therapeutics is a company based in Geneve (Switzerland) founded in 2002.. Addex Therapeutics has raised $71 million across 12 funding rounds from investors including Roche, Indivior and NIH. The company has 2 employees as of December 31, 2024. Addex Therapeutics offers products and services including Dipraglurant, ADX71149, and GABAB PAM.
- Headquarter Geneve, Switzerland
- Employees 2 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Addex Therapeutics Ltd
-
Annual Revenue
$452.6 K (USD)-74.64as on Dec 31, 2024
-
Net Profit
$7.79 M (USD)0as on Dec 31, 2024
-
EBITDA
$-2.76 M (USD)-28.81as on Dec 31, 2024
-
Total Equity Funding
$71 M (USD)
in 12 rounds
-
Latest Funding Round
$4.27 M (USD), Grant
Sep 20, 2023
-
Investors
Roche
& 22 more
-
Employee Count
2
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Addex Therapeutics
Addex Therapeutics is a publicly listed company on the SIX with ticker symbol ADXN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Addex Therapeutics
Addex Therapeutics offers a comprehensive portfolio of products and services, including Dipraglurant, ADX71149, and GABAB PAM. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets post-stroke and TBI recovery as an mGlu5 NAM.
mGlu2 PAM for substance use disorder and epilepsy treatment.
Addresses chronic cough and substance use disorders.
Unlock access to complete
Unlock access to complete
Funding Insights of Addex Therapeutics
Addex Therapeutics has successfully raised a total of $71M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $4.27 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Grant — $4.3M
-
First Round
First Round
(17 May 2004)
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Grant - Addex Therapeutics | Valuation |
investors |
|
| Jul, 2022 | Amount | Post-IPO - Addex Therapeutics | Valuation |
investors |
|
| Nov, 2020 | Amount | Post-IPO - Addex Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Addex Therapeutics
Addex Therapeutics has secured backing from 23 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Indivior and NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Addex Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Addex Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Addex Therapeutics Comparisons
Competitors of Addex Therapeutics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Addex Therapeutics
Frequently Asked Questions about Addex Therapeutics
When was Addex Therapeutics founded?
Addex Therapeutics was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Where is Addex Therapeutics located?
Addex Therapeutics is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Who is the current CEO of Addex Therapeutics?
Tim Dyer is the current CEO of Addex Therapeutics.
Is Addex Therapeutics a funded company?
Addex Therapeutics is a funded company, having raised a total of $71M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $2.8M, raised on May 17, 2004.
How many employees does Addex Therapeutics have?
As of Dec 31, 2024, the latest employee count at Addex Therapeutics is 2.
What is the annual revenue of Addex Therapeutics?
Annual revenue of Addex Therapeutics is $452.6K as on Dec 31, 2024.
What does Addex Therapeutics do?
Developer of oral small molecules for neurological disorders. The proprietary platform screens and identifies allosteric modulators. The product pipeline includes Diplaglurant for Parkinsons disease, specifically for Levodopa-induced Dyskinesia (PD-LID), ADX71149 for epilepsy, mGlu2 Nam for neurocognitive disorders, mGlu3 PAM Parkinsons disease, mGlu4 PAM for neurodegenerative disorders.
What products or services does Addex Therapeutics offer?
Addex Therapeutics offers Dipraglurant, ADX71149, and GABAB PAM.
Is Addex Therapeutics publicly traded?
Yes, Addex Therapeutics is publicly traded on SIX under the ticker symbol ADXN.
Who are Addex Therapeutics's investors?
Addex Therapeutics has 23 investors. Key investors include Roche, Indivior, NIH, New Leaf Venture Partners, and Fulcrum Pharma Developments.
What is Addex Therapeutics's ticker symbol?
The ticker symbol of Addex Therapeutics is ADXN on SIX.